PYXS (STOCKS)
Pyxis Oncology, Inc. Common Stock
$1.680000
-0.080000 (-4.55%)
Prev close: $1.760000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Thomas Civik
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $110.56M
- Employees
- 44
- P/E (TTM)
- -1.33
- P/B (TTM)
- 3.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.37 | $-0.38 | +0.0063 | +1.67% |
|
Dec 2025 (Q4)
|
$-0.29 | $-0.34 | +0.0534 | +15.55% |
|
Sep 2025 (Q3)
|
$-0.35 | $-0.35 | -0.0047 | -1.36% |
|
Jun 2025 (Q2)
|
$-0.30 | $-0.36 | +0.0587 | +16.36% |
Financial Statements
| Revenues | $13.86M |
| Nonoperating Income/Loss | $5.52M |
| Operating Expenses | $97.34M |
| Research and Development | $76.64M |
| Other Operating Expenses | $20.70M |
| Operating Income/Loss | -$85.87M |
| Income/Loss From Continuing Operations After Tax | -$81.74M |
| Income/Loss From Continuing Operations Before Tax | -$80.35M |
| Income Tax Expense/Benefit | $1.39M |
| Net Income/Loss | -$81.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$81.74M |
| Net Income/Loss Available To Common Stockholders, Basic | -$81.74M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.31 |
| Diluted Earnings Per Share | -$1.31 |
| Basic Average Shares | 188,241,983 |
| Diluted Average Shares | 188,241,983 |
| Assets | $64.30M |
| Current Assets | $45.57M |
| Cash | $41.00M |
| Prepaid Expenses | $3.08M |
| Other Current Assets | $1.49M |
| Noncurrent Assets | $18.73M |
| Fixed Assets | $7.54M |
| Other Non-current Assets | $11.19M |
| Liabilities | $33.03M |
| Current Liabilities | $16.53M |
| Accounts Payable | $4.99M |
| Other Current Liabilities | $11.54M |
| Noncurrent Liabilities | $16.50M |
| Equity | $31.27M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $31.27M |
| Liabilities And Equity | $64.30M |
| Net Cash Flow From Operating Activities | -$66.97M |
| Net Cash Flow From Operating Activities, Continuing | -$66.97M |
| Net Cash Flow From Investing Activities | $59.41M |
| Net Cash Flow From Investing Activities, Continuing | $59.41M |
| Net Cash Flow From Financing Activities | -$6.15M |
| Net Cash Flow From Financing Activities, Continuing | -$6.15M |
| Net Cash Flow | -$13.71M |
| Net Cash Flow, Continuing | -$13.71M |
| Comprehensive Income/Loss | -$81.78M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$81.78M |
| Other Comprehensive Income/Loss | -$49.00K |